By targeting surface markers on cancer cells, engineered synthetic receptors expressed on immune cells can be directed to ...

Tectonic Therapeutic has done well to advance its Fc-fusion protein candidate TX45 into a phase 2 study targeting patients ...

Team leaders will be looking for youth and college soccer players for our area who could become future stars for Buffalo's ...

A phase 3 trial evaluating sotatercept-csrk (Winrevair™) in adults with pulmonary arterial hypertension (PAH; World Health Organization Group 1) ...

Pre-season preparations have begun for members of the Calgary Wild FC. Players participated in an intake camp, testing the athletes' fitness, health and wellness. Calgary Wild FC will play in the ...

Discover seven companies operating in metabolomics, the field that could significantly boost precision medicine.

Kexing Biopharm Co., Ltd. (Stock Code: 688136.SH) recently announced that the Investigational New Drug Application (IND) of GB05, Human Interferon α1b Inhalation Solution, a self-developed product by ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

About TX45, a long-acting Fc-relaxin fusion protein TX45 is an Fc-relaxin fusion protein with optimized pharmacokinetics and biophysical properties that activates the RXFP1 receptor, the G-protein ...

Protein disulfide isomerases (PDIs) are essential enzymes that facilitate the proper folding of proteins and maintain protein quality within the endoplasmic reticulum.

TX45 improved both left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with preserved Ejection Fraction (“PH-HFpEF”), supporting endpo ...